Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate

[1]  G. Fenu,et al.  Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. , 2018, Multiple sclerosis and related disorders.

[2]  R. Malach,et al.  Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosis , 2018, Glia.

[3]  M. Filippi,et al.  Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment , 2018, Multiple sclerosis.

[4]  Roberta Lanzillo,et al.  Pregnancy decision-making in women with multiple sclerosis treated with natalizumab , 2018, Neurology.

[5]  Massimo Filippi,et al.  Cognition in multiple sclerosis , 2018, Neurology.

[6]  H. Wiendl,et al.  Distinct cognitive impairments in different disease courses of multiple sclerosis—A systematic review and meta-analysis , 2017, Neuroscience & Biobehavioral Reviews.

[7]  Robert E. Clark,et al.  Hippocampal area CA1 and remote memory in rats , 2017, Learning & memory.

[8]  P. Pasqualetti,et al.  Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability , 2017, Behavioural neurology.

[9]  M. Sela,et al.  Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis , 2016, Journal of Neuroimmunology.

[10]  H. Lassmann,et al.  Neurodegeneration in multiple sclerosis and neuromyelitis optica , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  T. Vanden Berghe,et al.  An outline of necrosome triggers , 2016, Cellular and Molecular Life Sciences.

[12]  Tim P. Moran,et al.  Anxiety and working memory capacity: A meta-analysis and narrative review. , 2016, Psychological bulletin.

[13]  T. Ziemssen,et al.  QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients , 2016, Journal of Neurology.

[14]  A. Dibernardo,et al.  Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review , 2016, Neurological Sciences.

[15]  Michael Tsoory,et al.  Dnmt3a in the Medial Prefrontal Cortex Regulates Anxiety-Like Behavior in Adult Mice , 2016, The Journal of Neuroscience.

[16]  Changjuan Wei,et al.  T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment , 2015, Scientific Reports.

[17]  Zhi-jun Zhang,et al.  LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice , 2015, Scientific Reports.

[18]  J. Thiran,et al.  Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis , 2015, BioMed research international.

[19]  G. Sun,et al.  The footprint of urban heat island effect in China , 2015, Scientific Reports.

[20]  Massimo Filippi,et al.  Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis , 2015, The Lancet Neurology.

[21]  Patrizia LoPresti.  Glatiramer Acetate Guards Against Rapid Memory Decline During Relapsing-Remitting Experimental Autoimmune Encephalomyelitis , 2015, Neurochemical Research.

[22]  Gabriele C DeLuca,et al.  Cognitive Impairment in Multiple Sclerosis: Clinical, Radiologic and Pathologic Insights , 2015, Brain pathology.

[23]  Stephen M. Rao,et al.  Cognitive impairment in multiple sclerosis: An 18 year follow-up study. , 2014, Multiple sclerosis and related disorders.

[24]  Qiong Zhou,et al.  Glatiramer acetate reverses cognitive deficits from cranial-irradiated rat by inducing hippocampal neurogenesis , 2014, Journal of Neuroimmunology.

[25]  D. Bannerman,et al.  An automated maze task for assessing hippocampus-sensitive memory in mice , 2014, Behavioural Brain Research.

[26]  Q. Pittman,et al.  Altered cognitive-emotional behavior in early experimental autoimmune encephalitis – Cytokine and hormonal correlates , 2013, Brain, Behavior, and Immunity.

[27]  R. Aharoni.  New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis , 2013, Expert review of clinical immunology.

[28]  Ryan D Ward,et al.  Inhibition of Mediodorsal Thalamus Disrupts Thalamofrontal Connectivity and Cognition , 2013, Neuron.

[29]  R. Aharoni.  The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. , 2013, Autoimmunity reviews.

[30]  Y. Assaf,et al.  Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate , 2013, Experimental Neurology.

[31]  H. D. de Vries,et al.  Grey matter damage in multiple sclerosis , 2013, Prion.

[32]  Mu-ming Poo,et al.  Neurotrophin regulation of neural circuit development and function , 2012, Nature Reviews Neuroscience.

[33]  F. Shi,et al.  Inflammation-Mediated Memory Dysfunction and Effects of a Ketogenic Diet in a Murine Model of Multiple Sclerosis , 2012, PloS one.

[34]  A. Vainshtein,et al.  Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. , 2011, Journal of autoimmunity.

[35]  M. Filippi,et al.  Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype , 2011, Human brain mapping.

[36]  D. Langdon.  Cognition in multiple sclerosis. , 2011, Current opinion in neurology.

[37]  M. Amato,et al.  Cognitive impairment in early stages of multiple sclerosis , 2010, Neurological Sciences.

[38]  S. Tiwari-Woodruff,et al.  Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE , 2010, Laboratory Investigation.

[39]  S. Dhib-jalbut,et al.  Interferon-β mechanisms of action in multiple sclerosis , 2010, Neurology.

[40]  Paul E. Gilbert,et al.  The role of the CA3 hippocampal subregion in spatial memory: A process oriented behavioral assessment , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  A. Holmes,et al.  Stress-induced prefrontal reorganization and executive dysfunction in rodents , 2009, Neuroscience & Biobehavioral Reviews.

[42]  F. Patti,et al.  Cognitive impairment in multiple sclerosis , 2009, Multiple sclerosis.

[43]  Michael Sela,et al.  Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis , 2008, Proceedings of the National Academy of Sciences.

[44]  M. Mcdermott,et al.  Cognitive function in relapsing multiple sclerosis: Minimal changes in a 10-year clinical trial , 2007, Journal of the Neurological Sciences.

[45]  P. Pavlidis,et al.  Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning , 2006, Proceedings of the National Academy of Sciences.

[46]  Michal Schwartz,et al.  Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Sela,et al.  The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Jiani Hu,et al.  Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis , 2005, Multiple sclerosis.

[49]  A. Karni,et al.  Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate , 2005, Journal of Neuroimmunology.

[50]  R. Arnon,et al.  Neurogenesis and Neuroprotection Induced by Peripheral Immunomodulatory Treatment of Experimental Autoimmune Encephalomyelitis , 2005, The Journal of Neuroscience.

[51]  G. Comi,et al.  Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes” , 2001, Neurology.

[52]  R. Gerlai.  A new continuous alternation task in T-maze detects hippocampal dysfunction in mice A strain comparison and lesion study , 1998, Behavioural Brain Research.

[53]  F. Barkhof,et al.  Causes, effects and connectivity changes in MS-related cognitive decline , 2016, Dementia & neuropsychologia.

[54]  H. Lassmann,et al.  Pathology of multiple sclerosis and related inflammatory demyelinating diseases. , 2014, Handbook of clinical neurology.

[55]  Robert Zivadinov,et al.  Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis , 2011, Journal of Neurology.

[56]  T. Ziemssen,et al.  Glatiramer acetate: mechanisms of action in multiple sclerosis. , 2007, International review of neurobiology.

[57]  J. Rawlins,et al.  T-maze alternation in the rodent , 2006, Nature Protocols.

[58]  Teresa Foo,et al.  : SYSTEMATIC LITERATURE REVIEW , 2004 .